Compare AROC & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AROC | MMED |
|---|---|---|
| Founded | 1990 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.6B |
| IPO Year | 2007 | 2025 |
| Metric | AROC | MMED |
|---|---|---|
| Price | $30.34 | $19.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $42.50 | $24.92 |
| AVG Volume (30 Days) | 1.4M | ★ 2.3M |
| Earning Date | 10-27-2026 | 11-10-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | ★ 74.29 | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | $1,489,818,000.00 | ★ $3,102,000,000.00 |
| Revenue This Year | $1.99 | $10.82 |
| Revenue Next Year | $7.78 | $8.28 |
| P/E Ratio | $37.88 | ★ N/A |
| Revenue Growth | ★ 28.70 | 14.25 |
| 52 Week Low | $22.88 | $10.65 |
| 52 Week High | $42.23 | $24.43 |
| Indicator | AROC | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 37.32 | 40.11 |
| Support Level | $25.17 | $10.68 |
| Resistance Level | $37.33 | $20.88 |
| Average True Range (ATR) | 0.89 | 0.81 |
| MACD | -0.01 | -0.38 |
| Stochastic Oscillator | 6.86 | 6.74 |
Archrock Inc is an energy infrastructure company focused on midstream natural gas compression. It is a provider of natural gas compression services, based on total compression fleet horsepower, to customers across the United States and a supplier of aftermarket services to customers that own compression equipment. The company operates through two segments: contract operations and aftermarket services. The contract operations segment includes designing, sourcing, owning, installing, operating, servicing, repairing, and maintaining its owned fleet of natural gas compression equipment, and generates the maximum revenue. The aftermarket services segment provides operations, maintenance, overhaul, and reconfiguration services, and sales of parts and components.
While MiniMed recently became an independent company again, it began in the 1980s as an upstart pioneer in developing and commercializing insulin pump therapy. Medtronic acquired MiniMed in 2001 and then spun it out in 2026 (though Medtronic still owns roughly 90% of MiniMed shares, which will be relayed to its shareholders as a tax-free distribution in the foreseeable future). MiniMed is the leader in traditional, tubed insulin pumps and also offers continuous glucose monitors, smart insulin pens, and other consumables.